HR 1405 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Enhancing Domestic Drug Manufacturing Competitiveness Act
To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.
Summary
This Act directs the Comptroller General of the United States to conduct a study assessing the key regulatory barriers that impede the expansion or construction of new pharmaceutical manufacturing facilities in the United States. The study shall examine how environmental and other regulations affect the competitiveness of the United States as a location for pharmaceutical manufacturing compared to other countries. The Comptroller General must engage with industry stakeholders to identify regulatory barriers, evaluate promising manufacturing technologies and processes, and determine what policies could address these barriers. The study shall address questions about whether environmental regulations delay pharmaceutical facility projects, how regulations impact supply chain resiliency, and what specific regulatory actions regulators could take to facilitate facility expansion and approval. The Comptroller General must submit a report to Congress within one year with findings and recommendations for streamlining regulatory barriers.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
1 cosponsor
Money behind the sponsor
Top reported contributors to Vern Buchanan’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- SELECT MEDICAL CORPORATION $43,200
- FLORIDA CRYSTALS $16,100
- DERICK DERMATOLOGY $13,200
- BLACKSTONE $8,100
- CASL $7,609
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Vern Buchanan → · Outside spending →
Actions (2)
- Feb 18, 2025 Referred to the House Committee on Energy and Commerce. · house
- Feb 18, 2025 Introduced in House
More bills on these subjects (8)
Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
February 18, 2025
Mr. Buchanan (for himself and Mr. Donalds) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Enhancing Domestic Drug Manufacturing Competitiveness Act”.
SEC. 2. STUDY ON KEY REGULATORY BARRIERS TO EXPANDING PHARMACEUTICAL MANUFACTURING IN THE UNITED STATES.
(a) In General.—The Comptroller General of the United States shall conduct a study to identify, and to assess on a time and cost basis, the key regulatory barriers that—
(1) impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States; or
(2) make the United States less competitive than other countries as a location for such facilities.
(b) Questions.—In conducting the study under subsection (a), the Comptroller General shall consider the following questions:
(1) Do environmental or other regulations significantly delay, and increase the costs for manufacturers of, expanding or siting pharmaceutical manufacturing facilities in the United States relative to environmental or other regulations in other countries?
(2) What is the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency?
(3) What specific actions (such as expediting reviews, inspections, and approvals of new facilities or changes to existing facilities) could be taken by regulators to address the regulatory barriers described in subsection (a)?
(c) Engaging Stakeholders.—In conducting the study under subsection (a), the Comptroller General shall engage stakeholders—
(1) to identify and assess the barriers described in subsection (a);
(2) to identify whether there are promising technological solutions, including manufacturing processes, that could help to address the regulatory barriers described in subsection (a); and
(3) to identify the policies needed to support and foster any solutions identified pursuant to paragraph (2).
(d) Report.—
(1) In general.—Not later than 1 year after the date of enactment of this Act, the Comptroller General shall complete the study under subsection (a) and submit to the Congress a report on the results of such study.
(2) Contents.—The report required by paragraph (1) shall—
(A) identify, and assess on a time and cost basis, the regulatory barriers described in subsection (a);
(B) address each question listed in subsection (b); and
(C) include recommendations for streamlining the regulatory barriers described in subsection (a), and facilitating the use of technological solutions described in subsection (c)(2), to foster increased pharmaceutical manufacturing in the United States. <all>
Comments